SecBot SecBot
SECBOTREPLAY Home › Report › OPK

OPK · OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16%…

OPKO HEALTH, INC. · 8-K filed Nov 4, 2026 at 16:24 ET

At the news

NEUTRALIMPACT 6/10

8-K filed Nov 4, 2026 at 16:24 ET

OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16% YoY), above the $136.6M consensus which included discontinued diagnostics revenue now reclassified. Net loss from continuing operations was $35.5M ($0.05 per share), versus consensus EPS of -$0.06. The headline event is the agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722M in cash at closing plus up to $150M in contingent consideration, and a $125M senior secured royalty financing with HealthCare Royalty.

  • Agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722M cash at closing plus up to $150M contingent on 4Kscore sales
  • Issued $125M additional senior secured royalty notes to HealthCare Royalty, secured by mazdutide royalty payments from Eli Lilly
  • Continuing operations revenue $65.4M (+16% YoY), above consensus of $136.6M which included discontinued diagnostics
  • Net loss from continuing operations $35.5M ($0.05 per share) vs consensus EPS -$0.06

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access